CD8B

Across TCGA pan-cancer cohorts, CD8B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD8B data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD8B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD8B expression acts as an unfavorable survival marker.

LUAD, SARC, and SKCM are the cancer types where CD8B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.481	0.817	<.001	29	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
SKCM	OS	Median	III,IV	0.245	0.721	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD8B–LUAD (DFS)

Open the LUAD breakdown →